|

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

RECRUITINGN/ASponsored by Dana-Farber Cancer Institute
Actively Recruiting
PhaseN/A
SponsorDana-Farber Cancer Institute
Started2022-08-11
Est. completion2026-07-01
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations1 site

Summary

The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of two groups: 1) Aerobic and resistance exercise, or 2) Usual care.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Patients must meet all criteria to be eligible, including travel to Dana-Farber Cancer Institute (DFCI) to collect research data to address the study question.
* Over 18 years old; children under the age of 18 will be excluded due to the rarity of the disease
* Histologically diagnosed of localized or metastatic prostate cancer
* Have been receiving androgen deprivation therapy (ADT) (i.e., luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonist and/or androgen receptor \[AR\] agonist/antagonist) for at least one month with a plan to continue ADT for at least 4 months at the time of recruitment
* Self-identify as Black
* Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist
* Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases
* Speak English and/or Spanish
* Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week
* Willing to travel to DFCI for necessary data collection
* Ability to communicate and complete written forms in English and/or Spanish

Exclusion Criteria:

* Are not receiving ADT (i.e., LHRH agonist/antagonist and/or AR agonist/antagonist)
* Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise
* Are not English or Spanish speaking
* Patients with secondary diagnosis (with the exception of basal cell carcinoma)
* Participate in more than 60 minutes of moderate or vigorous structured exercise/week
* Unable to travel to DFCI for necessary data collection
* May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

Conditions4

Androgen Deprivation TherapyCancerProstate CancerProstate Cancer Metastatic

Locations1 site

Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Christina Dieli-Conwright, PhD, MPH617-632-3800ChristinaM_Dieli-Conwright@dfci.harvard.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.